Sobi - Swedish Orphan Biovitrum AB (publ)

At Sobi, we are transforming the lives of people affected by rare diseases. A specialised international biopharmaceutical company, Sobi provides sustainable access to innovative therapies in the areas of haematology, immunology and specialty indications. Today, Sobi employs approximately 1,400 people across Europe, North America, the Middle East, Russia, Asia and North Africa. In 2019, Sobi's revenues amounted to SEK 14.2 billion. Sobi's share (STO:SOBI) is listed on Nasdaq Stockholm. You can find more information about Sobi at sobi.com.